FIGURE

Fig. 5

ID

ZDB-FIG-210117-57

Publication

Hsu et al., 2021 - L-Carnitine ameliorates congenital myopathy in a tropomyosin 3 de novo mutation transgenic zebrafish

Other Figures

All Figure Page

Back to All Figure Page

Fig. 5

l-Carnitine treatment increased mitochndria activity and the type I and type II myosin light chain expression of TPM3(E151G) larva. Mitochondrial respiration of TPM3 transgenic zebrafish via seahorse. a Schematic and oxygen consumption rate (OCR). OCR was measured under basal conditions followed by the sequential addition of oligomycin (0.5 μM), Carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP) (4 μM), rotenone (1 μM), or antimycin A (1 μM). b Basal respiration, c ATP production, and d proton leak of OCR measurement. e NADH-TR stains of TPM3(WT), TPM3(E151G) and one month of L-carnitine treated TPM3(E151G) transgenic zebrafish at 400X, scale bar is 50 µm. f the expression level of myh7 and gmyhz2 from TPM3 transgenic fish (F3) treated with l-carnitine from 28 hpf to 7 dpf cpmpared to TPM3(WT). Statistical significance was determined using a t-test, *0.01 < P ≤ 0.05; **0.001 < P ≤ 0.01; ***0.0001 < P ≤ 0.001; ****P ≤ 0.0001

Expression Data

Genes:	myh7 myhz2
Fish:	WT nn1016Tg nn1014Tg nn1015Tg
Condition:	chemical treatment by environment: (R)-carnitine
Anatomical Term:	whole organism
Stage:	Shield

Expression Detail

Antibody Labeling

Phenotype Data

Fish:	nn1014Tg nn1015Tg
Condition:	chemical treatment by environment: (R)-carnitine
Observed In:	aerobic respiration whole organism whole organism ATP
Stage Range:	Shield to Long-pec

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ J. Biomed. Sci.